Sheep anti Human Factor X polyclonal antibody [Biotin]

Biological control agents (BCA) are an alternative to chemical pesticides and an emerging strategy to safely eliminate plant pathogens.Trichodermaspp. are the most common fungi used as BCAs. They produce spores that are released into the air and can potentially interact with immune system of mammals. We previously showed thatTrichodermaaffects expression of genes encoding pattern recognition receptors (PRRs) and cytokines in mice. PRRs are involved in the recognition of microorganisms and can lead to pro-tumoral signaling. Here, we evaluated if mice injected with low doses of murine melanoma exhibited increased development of lung tumor when treated with conidia ofT. stromaticum. Mice treated withT. stromaticumand inoculated with B16-F10 melanoma cells exhibited significant increase in tumor uptake (p= 0.006) and increased number of visible nodules in the lungs (p= 0.015). We also analyzed mRNA expression levels of genes encoding PRRs in lung of mice exposed toT. stromaticumand demonstrated that mice treated withT. stromaticumconidia exhibited lower expression levels ofClec7aand increased expression ofTlr4(toll like receptor 4) compared to non-treated controls. The expression levels ofClec7aandTlr2were increased in mice treated withT. stromaticumand inoculated with murine melanoma compared to controls only inoculated with melanoma. Our results demonstrate that intranasal exposition toT. stromaticumincreases tumor in the B16-F10 model, which may raise concerns regarding the safety of its use in agriculture.

DOTA is commonly used for radiometal chelation in molecular imaging. Yet in the absence of a radiometal, DOTA is hypothesized to promote renal clearance of F-18-labeled peptide tracers. In light of an increasing interest in the use of F18 for PET, here the effect of DOTA is evaluated for the first time with an F-18-labeled tracer and is found to significantly improve the quality of images acquired through positron emission tomography (PET). We chose to image the peptide LLP2A that recognizes the transmembrane protein very-late antigen 4 (VLA-4) that is overexpressed by many cancers. Since it is known that [F-18]RBF3-PEG(2)-LLP2A derivatives gave low tumor uptake values and significant GI tract accumulation, this ligand thus represents an ideal means of testing the additive effects of a DOTA group on clearance while permitting a facile, userfriendly, one-step F-18-labeling. A newly designed RBF3-LLP2A bioconjugate with an appended DOTA moiety increased nearly 3-fold and reduced GI accumulation by more than 10-fold. The DOTA-AMBF(3)-PEG(2)-LLP2A was radiolabeled by isotope exchange and was purified by semiprep HPLC and C18 cartridge elution. Male C57BL/6J mice bearing B16-F10 melanoma tumors that overexpress the VLA-4 target were used to evaluate [F-18]DOTA-AMBF(3)-PEG(2)-LLP2A using a combination of static and dynamic PET scans, biodistribution studies, and blocking controls at 1 h post injection (p.i.). The precursor peptide was synthesized and F-18-labeled to provide formulations with mean (+/- SD) radiochemical purities of 95.9 +/- 1.8%, in radiochemical yields of 4.8 +/- 2.9% having molar activities of 131.7 +/- 50.3 GBq/mu mol. In vivo static PET images of [F-18]DOTA-AMBF(3)-PEG(2)-LLP2A provided clear tumor visualization, and biodistribution studies showed that tumor uptake was 9.46 +/- 2.19% injected dose per gram of tissue (%ID/g) with high tumor/muscle and tumor/blood contrast ratios of similar to 8 and similar to 10, respectively. Blocking confirmed the specificity of [F-18]DOTA-AMBF(3)-PEG(2)-LLP2A to VLA-4 in the tumor and the bone marrow. Dynamic PET showed clearance of [F-18]DOTA-AMBF(3)-PEG(2)-LLP2A mainly via the renal pathway, wherein accumulation in the intestines was reduced 10-fold compared to our previously investigated LLP2A's, while spleen uptake was at levels similar to previously reported LLP2A-chelator radiotracers. [F-18]DOTA-AMBF(3)-PEG(2)-LLP2A represents a promising VLA-4 radiotracer and provides key evidence as to how a DOTA appendage can significantly reduce GI uptake in favor of urinary excretion. Implications for the development of dual-isotope theranostics that exploit the use fluorine-18 for imaging and DOTA to chelate therapeutic metal cations for therapy are discussed.